The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
MAVIRET (AbbVie Pty Ltd)
Product name
MAVIRET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
181 working days (255)
Active ingredients
glecaprevir / pibrentasvir
Registration type
NCE/NBE
Indication
MAVIRET is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. This includes patients with HCV genotype 1 infection who were previously treated with either a regimen of an NS5A inhibitor or with an NS3/4A protease inhibitor but not both classes of inhibitors.